DSKY.F Stock Overview Manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Daiichi Sankyo Company, Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Daiichi Sankyo Company Historical stock prices Current Share Price JP¥28.40 52 Week High JP¥44.64 52 Week Low JP¥24.56 Beta 0.27 1 Month Change 6.77% 3 Month Change -11.60% 1 Year Change -9.15% 3 Year Change 30.94% 5 Year Change 15.67% Change since IPO 309.62%
Recent News & Updates
Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025 Jan 31 AstraZeneca PLC and Daiichi Sankyo’ ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Approves in the US for the Treatment of Adult Patients with Unresectable or Metastatic Hormone Receptor (HR)-Positive, HER2-Low (IHC 1+ or IHC 2+/ISH-) or Her2-Ultralow (IHC 0 with Membrane Staining) Breast Cancer Jan 28
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Jan 13
AstraZeneca and Daiichi Sankyo Voluntarily Withdrawn the Marketing Authorisation Application in the EU for datopotamab deruxtecan (Dato-DXd) Dec 26 Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn Dec 24
Quantum-Wild Phase 3 Trial of VANFLYTA Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML Dec 10 See more updates
Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025 Jan 31 AstraZeneca PLC and Daiichi Sankyo’ ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Approves in the US for the Treatment of Adult Patients with Unresectable or Metastatic Hormone Receptor (HR)-Positive, HER2-Low (IHC 1+ or IHC 2+/ISH-) or Her2-Ultralow (IHC 0 with Membrane Staining) Breast Cancer Jan 28
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Jan 13
AstraZeneca and Daiichi Sankyo Voluntarily Withdrawn the Marketing Authorisation Application in the EU for datopotamab deruxtecan (Dato-DXd) Dec 26 Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn Dec 24
Quantum-Wild Phase 3 Trial of VANFLYTA Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML Dec 10
Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025 Nov 14 Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS Nov 13
Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Nov 12
Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Nov 02
Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US Oct 02
Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy Oct 01
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer Sep 24
Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases Sep 14
Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO Sep 04
Daiichi Sankyo Company, Limited to Report Q2, 2025 Results on Oct 31, 2024 Aug 27
IHH Healthcare Berhad Provides Update on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited Aug 21
European Medicines Agency Validates Type II Variation Application for Daiichi Sankyo Company, Limited's ENHERTU Aug 19 Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer Aug 02
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer Jun 27
Daiichi Sankyo Company, Limited to Report Q1, 2025 Results on Jul 31, 2024 Jun 20 Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial May 28
AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow Apr 30
Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million. Apr 27 Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million. Apr 26
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer Apr 03
Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024 The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca Mar 05
Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024 Mar 02 AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US Feb 20
Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 Feb 02
Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024 Jan 31 Daiichi Sankyo and AstraZeneca Announces Two Phase 3 Trials of Datopotamab Dec 19
Daiichi Sankyo Company, Limited to Report Q3, 2024 Results on Jan 31, 2024 Nov 27
Daiichi Sankyo Company, Limited Appeals Amended Texas Court Judgement in Patent Dispute with Seagen Inc Nov 18
IHH Healthcare Berhad Announces Update on Claim Before the Tokyo District Court in Japan by NTK Against Daiichi Sankyo Company, Limited Nov 15
Daiichi Sankyo Company, Limited's VANFLYTA (quizartinib) Approves in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML Nov 10 Shareholder Returns DSKY.F US Pharmaceuticals US Market 7D 2.9% 4.2% -0.5% 1Y -9.1% 5.1% 24.3%
See full shareholder returns
Return vs Market: DSKY.F underperformed the US Market which returned 25.2% over the past year.
Price Volatility Is DSKY.F's price volatile compared to industry and market? DSKY.F volatility DSKY.F Average Weekly Movement 13.1% Pharmaceuticals Industry Average Movement 10.6% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.3%
Stable Share Price: DSKY.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DSKY.F's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.
Show more Daiichi Sankyo Company, Limited Fundamentals Summary How do Daiichi Sankyo Company's earnings and revenue compare to its market cap? DSKY.F fundamental statistics Market cap US$53.74b Earnings (TTM ) US$1.62b Revenue (TTM ) US$11.40b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DSKY.F income statement (TTM ) Revenue JP¥1.76t Cost of Revenue JP¥419.99b Gross Profit JP¥1.34t Other Expenses JP¥1.09t Earnings JP¥250.40b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
Earnings per share (EPS) 133.27 Gross Margin 76.11% Net Profit Margin 14.24% Debt/Equity Ratio 6.3%
How did DSKY.F perform over the long term?
See historical performance and comparison Dividends
1.4% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 08:56 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Daiichi Sankyo Company, Limited is covered by 32 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Atsushi Seki Barclays null null BNP Paribas Securities (Asia) Koichi Mamegano BofA Global Research
Show 29 more analysts 
